A Phase I, Pharmacokinetic and Biological Evaluation of a Small Molecule Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP-1), KU-0059436, in Patients With Advanced Tumours.
Latest Information Update: 28 Jul 2023
At a glance
- Drugs Olaparib (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Malignant melanoma; Ovarian cancer; Prostate cancer; Sarcoma; Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 13 Jul 2023 Status changed from active, no longer recruiting to completed.
- 19 Dec 2022 Planned End Date changed from 30 Dec 2022 to 31 Mar 2023.
- 22 Nov 2021 Planned End Date changed from 31 Dec 2021 to 30 Dec 2022.